RXDX(Delisted)
Prometheus·NASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About RXDX
Prometheus Biosciences, Inc.
A clinical-stage biotech company that develops novel therapeutic and companion diagnostic products for immune-mediated diseases
3050 Science Park Road, San Diego, California 92121
--
Prometheus Biosciences, Inc., was incorporated in Delaware on October 26, 2016. This is a biotechnology company that pioneered a precision medicine approach to discover, develop and commercialize novel therapeutic and companion diagnostic products. They leverage their proprietary precision medicine platform to identify new therapeutic targets and develop candidate therapeutic agents to participate in these targets. At the same time, they are developing companion diagnostic tests designed to identify patients who are more likely to respond to therapeutic drug candidates.
Company Financials
EPS
RXDX has released its 2023 Q1 earnings. EPS was reported at -0.86, versus the expected -0.91, beating expectations. The chart below visualizes how RXDX has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
RXDX has released its 2023 Q1 earnings report, with revenue of 1.10M, reflecting a YoY change of -71.80%, and net profit of -40.88M, showing a YoY change of -27.47%. The Sankey diagram below clearly presents RXDX's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
